UCSF 18th Annual Osteoporosis New Insights in Research, Diagnosis, and Clinical Care 2021
Format:2 videos + 1 pdf, size: 8.77 GB
Course Audience: epidemiology, pathophysiology physician
Overview:
Department: Epidemiology and Biostatistics
Activity Start Date: July 15, 2021
Activity End Date: July 15, 2021
Overview
Now in its 18th year, and presented by the department of epidemiology and Biostatistics of the University of California, San Francisco School of Medicine, this 1-day virtual course features an expert faculty that will discuss the epidemiology, pathophysiology, diagnosis, and treatment of osteoporosis. Specific topics will include the cell biology of osteoporosis, bone biomechanics, endocrine and nutrition aspects of osteoporosis, and advances in skeletal imaging. The course will also critically review current treatment options and preview new treatments. There will be an emphasis on recent developments and current controversies in the etiology, diagnosis, and management of osteoporosis.
Educational Objectives
An attendee completing this course will be able to:
- Provide appropriate pharmacological treatment for osteoporosis, including the use of new therapies;
- Evaluate the benefits and risks of continuing long-term antiresorptive and anabolic osteoporosis therapy and determine optimal treatment duration;
- Evaluate in whom and when a drug holiday would be appropriate for patients on bisphosphonates;
- Choose appropriate follow-on therapy for the anabolic therapies teriparatide, abaloparatide and romosozumab;
- Understand bone health issues in transgender patients.
*Note: these are continuous video recordings during the conference, they include individual lectures mentioned in the Detail section below
July 15 Part 1 (Video MP4 Format) ( 5 hours)
July 15 Part 2 (Video MP4 Format) ( 1 hours)
MEP22001_Syllabus (PDF Format)
*Detail:
Thursday, July 15, 2021
ANTIRESORPTIVE TREATMENT
8:00am Zoom Registration and Login
8:30 Bisphosphonate Efficacy: New Strategies to Maximize Fracture Risk Reduction Richard Eastell, MD, FRCP
8:50 Bisphosphonate Duration and Drug Holidays: Maximize Benefits and Minimize Risk Dennis M. Black, PhD
9:25 Q&A
9:40 Long-Term Treatment With and Following Denosumab Deborah E. Sellmeyer, MD
10:10 Q&A
10:20 Break
ANABOLIC TREATMENT
10:35 Anabolic Agents: Efficacy and Safety Clifford J. Rosen, MD
11:05 Incorporating Anabolic Treatments into Osteoporosis Regimens Anne L. Schafer, MD
11:30 Q&A
11:45am Lunch Break
SPECIAL TOPICS IN OSTEOPOROSIS
12:30pm Metabolic Bone Disease in the Setting of Chronic Kidney Disease Paul D. Miller, MD, HDSc (HON)
1:00 Q&A
1:10 Stress Fractures in Premenopausal Women and Young Men Mary L. Bouxsein, PhD
1:30 Q&A
1:40 DXA Interpretation and Pitfalls Deborah Sellmeyer, MD
2:10 Q&A
2:20 Break
2:35 Racial Differences and Disparities in Osteoporosis Care Nicole C. Wright, PhD, MPH
3:00 Q&A
3:10 Clinical Roundtable: Q&A with a Panel of Physicians Deborah E. Sellmeyer, MD Anne L. Schafer, MD Clifford J. Rosen, MD Steven T. Harris, MD, FACP, FASBMR Dolores M. Shoback, MD
3:45 Adjourn